Caris Life Sciences, Inc. reported $990M of revenue over the trailing twelve months, +85% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $990M (to Q2 2026). Net income: $105M, trailing twelve months to Q2 2026. Free cash flow: $24M, trailing twelve months to Q2 2026. Operating margin: 14%, trailing twelve months to Q2 2026.

CAICaris Life Sciences, Inc.

Healthcare

$29.66-9.0% 1Y

$29.66

$14.5552 weeks$32.95

CAI as reported

Caris Life Sciences, Inc. reported $990M of revenue over the trailing twelve months, +85% on the year before. 9 reported series are charted on this page, each one as filed.

$990M

Revenue, trailing twelve months · to Q2 2026 · +85% against the twelve months before

Net income: $105M
Net income · −138% year on year · trailing twelve months to Q2 2026
Free cash flow: $24M
Free cash flow · −117% year on year · trailing twelve months to Q2 2026
Operating margin: 14%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CAI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$990M	+85%	Q2 2026
Net income	$105M	−138%	Q2 2026
EPS	$1.69	−111%	Q2 2026
Operating margin	14%	n/a	Q2 2026
Net margin	9.7%	n/a	Q2 2026
ROE	−6.8%	n/a	Q2 2026
ROA	−3.4%	n/a	Q2 2026
ROIC	7.1%	n/a	Q2 2026
Free cash flow	$24M	−117%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.